Opana er and Hyperhidrosis - a phase IV clinical study of FDA data

Summary:

Hyperhidrosis is reported as a side effect among people who take Opana er (oxymorphone hydrochloride), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Opana, and have Breakthrough pain.

The phase IV clinical study analyzes which people have Hyperhidrosis when taking Opana er. It is created by eHealthMe based on reports of 33,673 people who have side effects when taking Opana er from the FDA, and is updated regularly.

What is Opana er?

Opana er has active ingredients of oxymorphone hydrochloride. It is often used in pain. eHealthMe is studying from 33,986 Opana er users. Check the latest studies of Opana er.

What is Hyperhidrosis?

Hyperhidrosis (abnormally increased sweating) is found to be associated with 2,539 drugs and 3,546 conditions by eHealthMe. Check the latest studies of Hyperhidrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

33,673 people reported to have side effects when taking Opana er.
Among them, 57 people (0.17%) have Hyperhidrosis.

Among these 57 people:

How long have people been on Opana er when they have Hyperhidrosis? *

What is the gender of people who have Hyperhidrosis when taking Opana er? *

female: 48.21 %
male: 51.79 %

What is the age of people who have Hyperhidrosis when taking Opana er? *

What are other drugs people take besides Opana er? *

Opana: 9 people, 15.79%
Percocet: 8 people, 14.04%
Tramadol Hydrochloride: 5 people, 8.77%
Lyrica: 4 people, 7.02%
Morphine Sulfate: 4 people, 7.02%
Depodur: 3 people, 5.26%
Oxymorphone Hydrochloride: 3 people, 5.26%
Xanax: 3 people, 5.26%
Kadian: 2 people, 3.51%
Crestor: 2 people, 3.51%

What are other side effects people have besides Hyperhidrosis? *

Drug Ineffective: 16 people, 28.07%
Nausea (feeling of having an urge to vomit): 13 people, 22.81%
Constipation: 12 people, 21.05%
Headache (pain in head): 12 people, 21.05%
Stress And Anxiety: 10 people, 17.54%
Abdominal Pain Upper: 9 people, 15.79%
Feeling Abnormal: 9 people, 15.79%
Drug Withdrawal Syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation): 8 people, 14.04%
Nausea And Vomiting: 6 people, 10.53%
Diarrhea: 6 people, 10.53%

What are the existing conditions these people have? *

Breakthrough Pain: 4 people, 7.02%
Fibromyalgia (a long-term condition which causes pain all over the body): 3 people, 5.26%
Stress And Anxiety: 2 people, 3.51%
Neck Pain: 2 people, 3.51%
High Blood Pressure: 2 people, 3.51%
Intervertebral Disc Degeneration (spinal disc degeneration): 2 people, 3.51%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 3.51%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 1.75%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 1 person, 1.75%
Prostate Cancer: 1 person, 1.75%

* Approximation only. Some reports may have incomplete information.

Do you take Opana er and have Hyperhidrosis?

- Check whether Hyperhidrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opana er:

Opana er (33,986 reports)

Hyperhidrosis treatments and more:

Hyperhidrosis (147,206 reports)

Browse all side effects of Opana er:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperhidrosis:

Hyperhidrosis (2,539 drugs)

Browse all the conditions that are associated with Hyperhidrosis:

Hyperhidrosis (3,546 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on oxymorphone hydrochloride (the active ingredients of Opana er) and Opana er (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.